Uncategorized

Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies – Investor’s Business Daily

Posted on Author Tim Hodges Comments Off on Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies – Investor’s Business Daily
  1. Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies  Investor’s Business Daily
  2. Second patient death reported with gene therapy for muscular dystrophy  Yahoo Finance
  3. Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne  Sarepta Therapeutics
  4. After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry  statnews.com
  5. Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures  WSJ